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Abstract
Severe postpartum hemorrhage (sPPH) is an obstetric emergency that needs prompt and effective therapy to reduce the risk of
complications. In this study, women who developed sPPH (study cohort, n ¼ 27) were treated according to a standardized
management protocol prescribing sequential administration of uterotonic drugs, crystalloids, tranexamic acid, labile blood
products, low-dose fibrinogen, and recombinant activated factor VII (rFVIIa). This group was compared to patients treated with
different strategies during 2 preceding periods: an in-house guideline regulating the administration of rFVIIa (historical cohort 1, n
¼ 20) and no specific guideline (historical cohort 2, n ¼ 27). The management protocol was used over 33 months. The study
cohort had a lower estimated blood loss (P ¼ .004) and required less red blood cell concentrates (P ¼ .007), fresh frozen plasma
units (P ¼ .004), and platelet concentrates (P ¼ .020) compared to historical cohort 1 and historical cohort 2, respectively.
The necessity of emergency postpartum hysterectomy was lower in the study group (P ¼ .012). In conclusion, in patients with
sPPH treated with this standardizedmanagement protocol, we observed a decreased requirement of labile blood products and lower
need to proceed to emergency postpartum hysterectomy.
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Introduction
Severe postpartum hemorrhage (sPPH) remains an obstetric
emergency and a leading cause of maternal death.1,2 Uterus-
conserving strategies to stop bleeding, for example, hemostatic
drugs, interventional radiology, and surgical measures includ-
ing compression sutures, should be coordinated and implemen-
ted according to standard operating procedures.3-5 Emergency
postpartum hysterectomy (EPH) is performed when all conser-
vative lifesaving treatments have failed to achieve hemostasis6
but might end the bleeding only in 50% of the cases.7 So far,
there is no gold standard treatment for sPPH.8 Evidence sup-
ports administration of uterotonics after delivery in order to
prevent and control postpartum hemorrhage (PPH).9-11 How-
ever, pharmacological uterotonic agents and new surgical tech-
niques to control sPPH have limited impact on the reduction in
EPH,12,13 which remains associated with a high rate of mor-
bidity and mortality.14 The role of hemostatic drugs in sPPH is
not fully clarified. Prophylactic application of tranexamic acid
for prevention of PPH decreases postpartum blood loss after
vaginal and cesarean delivery.15-18 Its therapeutic use is
effective in PPH,19,20 and therefore, tranexamic acid is recom-
mended for obstetric bleeding by the 2013 and 2016 guidelines
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of the European Society of Anaesthesiology.21,22 Early admin-
istration of tranexamic acid reduces death due to bleeding in
women with PPH.23 More controversial is the role of recom-
binant activated factor VII (rFVIIa) in obstetric hemorrhage
because its usefulness, safety, optimal dose, and timing for
administration have not been determined so far.24,25 Recom-
binant activated factor VII can be considered as second-line
hemostatic therapy,22 but other guidelines limit its use.8 The
new WHO recommendations on prevention and treatment of
PPH do not even mention rFVIIa but recommend the imple-
mentation of a standardized institutional approach for the
management of PPH, without defining the place of hemo-
static drugs.26
In 2009, the institutional Transfusion Committee of the
University Hospital, Inselspital, Bern, together with a multi-
disciplinary working group including obstetricians, anesthe-
siologists, hematologists, blood transfusion specialists, and
midwives developed a standardized management protocol for
PPH after vaginal and cesarean delivery, respectively. This
protocol, based on the literature review and personal clinical
experience,5,27 was designed to achieve early recognition and
coordinated treatment of PPH with a predefined sequence of
surgical and medical interventions. The objective of the present
study was to evaluate this standardized management protocol
in patients with sPPH compared to 2 different cohorts treated
before adoption of this strategy.
Materials and Methods
This single-center study was conducted at the tertiary care
University Hospital, Inselspital, of Bern, Switzerland, in
accordance with the guidelines for human participant
research. Approval was obtained from the local ethics com-
mittee (decision number 197/08). Patients with sPPH treated
with a standardized management protocol—study cohort—
were compared to patients previously treated with an in-
house guideline for rFVIIa in massive bleeding (historical
cohort 1) and to patients treated without specific guideline
(historical cohort 2, Figure 1).
Study Cohort
All patients aged 18 years or older who developed sPPH after
vaginal delivery or cesarean section between April 1, 2010, and
December 31, 2012, were prospectively included. Severe PPH
was defined as continuous bleeding of more than 1500 mL
within 24 hours after birth.28,29 In order to reduce inaccuracies,
estimation of blood loss during the study was verified in a
standard manner by weighing all gauzes, sponges, and blood
obtained in collection systems.
From April 1, 2010, to December 31, 2012, all patients were
treated according to the standardized management protocol
depicted on Figures 2 and 3. Specifically, in the event of severe
blood loss during or after birth, the medical team treating the
parturient released a “PPH code,” which is an emergency call
allowing clear and precise communication between
multidisciplinary team members (senior obstetrician, anesthe-
siologist, midwives, hematology consultant, blood transfusion
specialist, laboratory staff, and transport service for medica-
ments and blood products) that a PPH is in process. Once PPH
has been identified, monitoring, mechanical, and physiological
measures to stimulate the uterine contraction were promptly
started. They included uterine massage, bimanual uterine com-
pression, and external aortic compression. Pharmacological
measures included early administration of uterotonic drugs,
fluids, tranexamic acid, and—if indicated—calcium. The max-
imum amount of warmed volume replacement was limited for
colloids (ie, hydroxyethyl starch) to a total of 20 mL/kg body
weight. Simultaneously, a package containing a predefined
number of blood and hemostatic product units was sent by
emergency transport from the central laboratory to the obstetric
surgical suite. The “emergency package” contained 4 units of
packed red blood cells (RBCs), 4 units of fresh frozen plasma
(FFP), 1 platelet (PLT) concentrate, 2 g of fibrinogen concen-
trate, and rFVIIa at a dose of 60 mg/kg body weight.30 Labile
blood products were given in fixed ratios of 1:1, as this com-
bination had been shown to improve survival in trauma.31,32
Recombinant activated factor VII was administered addition-
ally, if bleeding persisted after transfusion of 4 RBCs, 4 FFP
units, and 2 g of fibrinogen. Surgical interventions included the
identification and repair of lower genital tract lesions, the man-
ual and instrumental uterine revision and curettage, uterine
tamponade by a balloon catheter or by surgical towels, lapar-
otomy and uterine compression sutures (B-Lynch or Pereira
sutures, Hayman suture technique, square sutures), and uterine
artery embolization. More blood products could be ordered by
code if all products on site were being administered and bleed-
ing still persisted. In this case, a second identical package was
sent. A third demand of products was possible in case of per-
sistent bleeding and included 2 g of fibrinogen and 1250 IU
FXIII. After consulting the hematologist, eventually a third
dose of rFVIIa was sent. If bleeding still persisted, hysterect-
omy was performed (Figures 2 and 3). In the event that bleed-
ing stopped and supplemental products were judged to be
unnecessary, the remaining components of the “emergency
package” were sent back to the central laboratory.
Figure 1. Study design.
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Order 3rd round of Code PPH
Repeat labs: PT, aPTT, Fbg, TT, 
ROTEM, Hb, BGA, Ca
++
Postpartum Hemorrhage After Vaginal Delivery1
O
B
S
O
R
Obstetric Team
Emergency Call for 
Anesthesia Team
Tel 181 5912
Obstetric assessment
• tone (uterotonic agents)
• trauma (inspect birth canal, 
exclude uterine rupture)
• retained placenta 
(sonography)
Decision support for transfer to OR:
Heart Rate > 100/min
(consider relative bradycardia in beta blocked, athlete, pacemaker)
Take baseline labs:
Hb, PLTs, PT/INR, aPTT, Fbg, 
TT, FXIII, ROTEM
Call Code PPH
Tel 2-3307
order 4 RBCs, 4 FFP, 1PLT, 
2g Fibrinogen, rFVIIa
Oxytocin 5 IU i.v., then     
10-20 IU/2h infusion
and/or
Misoprostol 1000 µg
rectally
Methyl ergometrine
0.2 mg i.m. or i.v.
Sulprostone  
100-500 µg/h i.v.   
infusion
Curettage
Surgical repair of genital tract trauma 
Uterine tamponade: surgical or by balloon 
catheter (optional)
Laparotomy
Compression sutures
Ligation uterine arteries or internal iliac 
artery
- Warmed Ringer´s and 
HES 6% (20ml/kg max.)
- TXA 1g i.v. (10 min)
if not yet given
- 2 units RBC O neg
as required
- 4 RBCs, 4 FFP, 1 PLT 
- Consider 1g Ca gluconate 
- Fibrinogen 2g iv  if  Fbg <1g/L
- if bleeding continues 
after 4 RBCs and 4 FFP:
1st dose rFVIIa 60 µg/kg i.v
- repeat 2g Fibrinogen i.v.  
- consult hematology 181-6220
for:
-- FXIII 1250 IU i.v. 
-- 3rd dose rFVIIa
60 µg/kg i.v.
O2 10-15 l/min per reservoir FM,
large IV lines
set up LEVEL1 and
autotransfusion device
RSI – Intubation 
Level 1, 
Radial arterial line 
Target:
• MAP 50 mmHg, pH > 7.2
• Hb > 85 g/L, Temp > 35°C
• PLTs > 50 G/L
- Fibrinogen 2 g i.v. if Fbg <1g/L 
- 4 RBCs, 4 FFP, 1 PLT, Ca++
- 2nd dose rFVIIa 60 µg/kg i.v.
Oxytocin 10-20 IU/2h infusion
Sulprostone 100-500 µg/h 
infusion
TXA 1 g in 100 ml 
NaCl i.v. (10 min) 
Early stage, stable hemodynamics: Consider uterine artery embolisation (interventional radiology)
1 WHO: Persistent bleeding:     
EBL > 500 ml after vaginal delivery  
EBL > 1000 ml after caesarean section
Emergency Hysterectomy
Anesthesia Team
Persistent bleeding
after 4-6 RBCs, 4 FFP, 1PLT, tamponade & values within target
Order 2nd round of Code PPH
Tel 2-3307
Repeat labs: PT, aPTT, Fbg, TT, 
ROTEM, Hb, BGA, a
++
Continue normovolemic 
transfusion, target:
• PLTs > 50 G/L
• Fbg > 1 g/L
• MAP 50 mmHg, pH > 7.2
If hemodynamically stable, consider uterine 
artery embolisation 
Persistent bleeding
O
R
Uterine massage
Bimanual uterine compression
External aortic compression
Figure 2. Protocol for the treatment of PPH after vaginal delivery. PPH indicates postpartum hemorrhage.
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PPH During Cesarean Delivery1 (Expected)
O
B
S
Call 2-3307 Code PPH, order
4 units RBCs, 4 FFP, 1 PLT, 
2g Fibrinogen, rFVIIa 60 µg/kg
Send coag labs:
PT, aPTT, Fbg, TT, FXIII,
ROTEM
Persistent bleeding
after    
4-6 RBCs / 4 FFP / 1 PLT
Persistent bleeding 
despite continued  
transfusion
- HES 6% (130/0.4) max. 20ml/kg
- TXA 1 g i.v. (10 min)
- 4 RBCs (from OR blood refrigerator)
- 4 RBCs, 4 FFP, 1 PLT 
- Consider 1 g Ca gluconate 
- Fibrinogen 2g i.v. if Fbg <1g/L
- if bleeding continues 
after 4 RBCs and 4 FFP:
1st dose rFVIIa 60 µg/kg i.v
- repeat 2g Fibrinogen i.v.  
- consult hematology 181-6220 for:
-- FXIII 1250 IU i.v. 
-- 3rd dose rFVIIa 60 µg/kg i.v.
O2 10-15 l/min per reservoir FM,
large IV lines, arterial line, 
LEVEL1, autotransfusion device
RSI (consider converting SSS)
Target:
• MAP 50mmHg, pH > 7.2
• Hb > 85 g/L, Temp > 35°C
• PLTs > 50 G/L
Order 2nd round of Code PPH           
Repeat labs:
PT, aPTT, Fbg, TT, ROTEM,
Hb, BGA, Ca
++
Persistent bleeding
- Fibrinogen 2 g i.v. if  Fbg <1g/L 
- 4 RBCs, 4 FFP, 1 PLT, Ca++
- 2nd dose rFVIIa 60 µg/kg i.v.
Carbetocin 100 µg i.v. (not in            
pre-eclampsia/eclampsia)
Oxytocin 10-20 IU (infusion)
Consider Misoprostol 1000 µg
(rectally)
Sulprostone 100-500 µg/ h i.v. 
(infusion pump)
Methyl ergometrine 0.2 mg i.v. 
(not in HTN, pre-eclampsia)
Compression 
sutures, vascular 
ligatures
Emergency 
Hysterectomy
Intraoperative 
autotransfusion
Volume replacement
Blood product transfusion 
O
R
Baseline labs: 
Hb, PLTs, PT/INR, 
aPTT, Fbg, TT, FXIII, 
ROTEM
Placenta previa, accreta, increta or percreta and/or uterine myoma
Individualized surgical and anesthesiologic management should be planned and documented preoperatively with the patient. 
Continue normovolemic 
transfusion, target:
• PLTs > 50 G/L
• Fbg > 1 g/L
• MAP 50 mmHg,  pH > 7.2
RULE: 
repeat laboratory 15-30 min after each hemostatic intervention
1 WHO: Persistent bleeding, 
EBL > 500 ml after vaginal delivery  
EBL > 1000 ml after caesarean section
Anesthesia Team
Cesarean Section
Obstetric Team
Persistent bleeding
PPH
Order 3nd round of Code PPH           
Repeat labs:
PT, aPTT, Fbg, TT, ROTEM,
Hb, BGA, Ca
++
If hemodynamically stable, consider uterine artery embolisation (interventional radiology)
Figure 3. Protocol for the treatment of PPH during cesarean delivery. PPH indicates postpartum hemorrhage.
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Historical Cohort 1
From January 1, 2005, to December 31, 2007, all patients with
sPPH were treated with uterotonic drugs, such as oxytocin,
methylergometrine, misoprostol, sulprostone, fluid manage-
ment, RBCs, FFP, and/or fibrinogen and PLT transfusion
according to current practice. If conservative and surgical mea-
sures failed and massive bleeding persisted after transfusion of
8 RBCs and 4 units of FFP, all patients received rFVIIa at a
dose of 60 mg/kg body weight, according to an in-house guide-
line for treatment of massive bleeding.30 If blood loss was still
ongoing, a second rFVIIa dose was given. If uncontrollable
bleeding persisted after this second rFVIIa application, hyster-
ectomy was performed. The protocol is detailed in the Supple-
mental Table 1.30
Historical Cohort 2
From January 1, 2008, to March 31, 2010, no specific treatment
guidelines were followed. The obstetrical and medical care
teams performed the same procedures as listed above for the
preceding period. However, the decision whether and when to
administer blood products, hemostatic agents, such as tranexa-
mic acid, fibrinogen, and rFVIIa, was left to the discretion of
individual team leaders, according to their best clinical and
personal experience. During this period, the approach and man-
agement of a single patient were not standardized. Therefore,
the sequence of the same procedures may have been different
between the patients. Data from all patients with sPPH as pre-
viously defined were obtained from medical records. To avoid
bias in the inclusion, all patients were searched with a hospital
computer code for PPH. Furthermore, all patients transfused
after birth during this time period were checked for the inclu-
sion criteria of sPPH.
All clinical data were documented by the treating physi-
cian(s) or nurse(s)/midwife(s). Missing clinical data were
searched in the original documentation and in the transfusion
medicine record system. The amount of blood obtained
through recovery techniques and reinfused was computed.
Patients were followed until their hospital discharge. The fol-
lowing data were obtained from each woman: age, weight,
parity, gravidity, gestational age (weeks), estimated total
blood loss, risk factors predisposing to PPH, mode of deliv-
ery, cause of PPH, complete or incomplete placenta and mem-
branes, infused fluids, blood product replacement, medical
and surgical treatment, duration of bleeding prior to adminis-
tration of hemostatic agents including rFVIIa administration,
necessity of EPH, thromboembolic complications, death, and
cause of death.
Statistical Analysis
All quantitative data are presented as number, percentage (%),
median and interquartile range (IQR), minimum–maximum
(min–max), mean, and standard deviation (SD), as appropriate.
Nonparametric statistics were applied and all analyses were
performed with SigmaPlot 12.3 (Systat Software, Inc. Chicago,
Illinois). Comparisons between various groups were performed
with the Kruskal-Wallis test or w2 test for categorical data. A
Mann-Whitney U test was used for independent samples. Size
effect was determined between groups of similar size according
Table 1. Demographic Data of Total Cohort With Severe Postpartum Hemorrhage (sPPH).
Historical Cohort 1
n ¼ 20
Historical Cohort 2
n ¼ 27
Study Cohort
n ¼ 27 P Value
Maternal age (years), median (IQR) 32 (28-36) 36 (32-37) 31 (27-33) .025
<20 years 0 0 1
20-34 years 14 12 20
35 years 6 15 6
Parity .491
Primiparous 10 9 10
Multiparous 10 18 17
Gestation .067
Singleton 18 27 22
Multiples 2 0 5
Gestational age (weeks) .385
<28 weeks 0 1 2
28-36 weeks 5 12 11
37-41 weeks 15 14 14
Maternal weight (kg) .788
Median (IQR) 70 (57-80) 70 (62-82) 70 (64-83)
Cause of PPH (n) .023
Uterus or parametria lesion 0 7 1
Uterine atony 15 14 16
Placenta retention 5 6 10
Preexisting coagulation defect 0 0 0
Abbreviations: IQR, interquartile range; PPH, postpartum hemorrhage.
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to Cohen d by calculating the mean difference between 2
groups and then dividing the result by the pooled SD. Between
groups of different size Hedges’ g was calculated, which pro-
vides a measure of effect size weighted according to the rela-
tive size of each sample. A 2-tailed P value of <.05 was
considered significant.
Results
During the study period, data from 74 patients who had sPPH
were collected: 20 in the historical cohort 1 and 27 in both the
historical cohort 2 and the study group. The patients’ charac-
teristics are presented in Table 1. Median age was 32 years
(IQR 28-36 years) for the cohort 1, 36 years (IQR 32-37 years)
for the cohort 2, and 31 years (IQR 27-33 years) for patients of
the study group (P ¼ .025). Uterine atony was the most fre-
quent cause of sPPH (Table 1).
There were 7 vaginal deliveries each in both historical
cohorts and 9 in the study group (P ¼ .762), resulting in a
total of 23 vaginal and 51 cesarean deliveries. No differences
in the incidence of embolization or ligation of pelvic vessels
were observed between the 3 groups (both interventions
together P¼ .133). Five (25%) women in the historical cohort
1, 10 (37%) in the cohort 2, but only 1 (3.7%) in the study
group underwent hysterectomy, showing a reduced necessity
for this procedure after introduction of the standardized pro-
tocol (P ¼ .012, Table 2).
The estimated total blood loss was significantly lower in the
study cohort (study cohort: median 3000 mL [IQR 2000-4000
mL] vs historical cohort 1: 4500 mL [IQR 3000-5500 mL] and
historical cohort 2: 6000 mL [IQR 3000-6500 mL], respec-
tively, P ¼ .004). The total amount of infused crystalloids was
similar in the 3 groups, whereas the amount of colloids admi-
nistered was lower in the study cohort (P < .001, Table 3).
The number of transfused labile blood product units was
lower in the study group compared to both historical cohorts
(Table 2). Median RBC units transfused decreased from 12
(IQR 8-16) in cohort 1 and 12 (IQR 6-16) in cohort 2 to 6 (IQR
3-9) in the study cohort (P ¼ .007). A similar trend was
observed for FFP units (historical cohort 1: median 10 [IQR
7-13], historical cohort 2: median 10 [IQR 4-12], study group:
median 5 [IQR 2-8], P ¼ .004) and for PLT concentrates
(median 2 [IQR 1-3], median 1 [IQR 0-2], and median 1 [IQR
0-1], respectively, P¼ .020). Analysis of study cohort omitting
patients undergoing ligation (n¼1) or embolization of pelvic
vessels (n¼4) leaving 22 patients in the study cohort (Table 2)
showed unchanged results regarding estimated blood loss
(median 3000 mL, IQR 2000-4000 mL) and number of trans-
fused labile blood products (total RBC units: median 5 [IQR 3-
8], FFP: median 5 [IQR 2-8] and PLT concentrates: median 0
[IQR 0-1]). According to the protocol, a significant increase in
tranexamic acid and fibrinogen administration was observed in
the study group (P < .001, Table 2). The proportion of patients
receiving rFVIIa decreased from 100% (historical cohort 1) to
55% (historical cohort 2) and 52% (study cohort), respectively
Table 2. Treatment of sPPH: Results Expressed as Medians and Interquartile Ranges (IQR) and Numbers and Percentages (%) of Patients
Receiving Defined Amounts of Blood Products.
Historical Cohort 1
n ¼ 20
Historical Cohort 2
n ¼ 27
Study Cohort
n ¼ 27 P Value
Allogeneic Transfusion
RBCs median (IQR) 12 (8-16) 12 (6-16) 6 (3-9) .007
4, n (%) 2 (10) 5 (18.5) 13 (48)
5-8, n (%) 5 (25) 5 (18.5) 8 (30)
>8, n (%) 13 (65) 17 (63) 6 (22)
FFP median (IQR) 10 (7-13) 10 (4-12) 5 (2-8) .004
4, n (%) 2 (10) 8 (30) 13 (48)
5-8, n (%) 6 (30) 5 (18) 10 (37)
>8, n (%) 12 (60) 14 (52) 4 (15)
PLT median (IQR) 2 (1-3) 1 (0-2) 1 (0-1) .020
2, n (%) 14 (70) 25 (93) 23 (85)
>2, n (%) 6 (30) 2 (7) 4 (15)
Hemostatic agents
Tranexamic acid 5 (25%) 17 (63%) 27 (100%) <.001
Fibrinogen 1 (5%) 2 (7%) 20 (74%) <.001
rFVIIa 20 (100%) 15 (55%) 14 (52%) .018
FXIII 0 0 0
Surgical procedures
Ligation of pelvic vessel 0 1 (3.7%) 1 (3.7%) .687
Embolization of pelvic vessel 1 (5%) 0 4 (15%) .092
Hysterectomy 5 (25%) 10 (37%) 1 (3.7%) .012
Abbreviations: FFP, fresh frozen plasma; PLT, platelet concentrates; RBC, red blood cell concentrates; rFVIIa, recombinant activated factor VII; sPPH, severe
postpartum hemorrhage.
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(P ¼ .018). The dose of administered rFVIIa calculated in mg/
kg body weight was similar in all 3 groups (historical cohort 1:
median 63.4 mg/kg [IQR: 57.3-68.0, min–max: 24.0-92.3], his-
torical cohort 2: median 60.0 mg/kg [IQR: 57.1-69.5, min–max:
50.0-114.2], and study cohort: median 59.5 mg/kg [IQR: 54.2-
66.6, min–max 31.2-70.4]; P¼ .586). The dose of administered
fibrinogen increased in the study cohort (study cohort: median
2 g [IQR: 0-2, min–max: 0-4] and historical cohorts 1 and 2:
median 0 g [IQR: 0-0, min–max: 0-1], P < .001).
In the study cohort, bleeding duration was shorter than in
both historical cohorts 1 and 2. Of note, duration of bleeding
before rFVIIa administration was shorter in the study cohort
(n¼ 14, median 135 minutes, IQR 108-173 minutes) compared
to historical cohort 1 (n ¼ 20, median 328 minutes, IQR 151-
640 minutes) and historical cohort 2 (n ¼ 15, median 190
minutes, IQR 150-240 minutes), respectively (P ¼ .021). As
indicated in Table 4, the management protocol used in the
study cohort especially impacted the number of blood products
transfused before specific hemostatic therapy, shortening the
time delay to the decision to administer fibrinogen and/or
rFVIIa. The number of transfused blood products before
administration of hemostatic agents (fibrinogen and/or rFVIIa
if necessary) was significantly lower in the study cohort
(RBCs, median 4 [IQR 3-7]; FFP, median 4 [IQR 2-6]; and
PLT, median 0 [IQR 0-1]) compared to historical cohort 1
(RBCs, median 9 [IQR 6.5-15]; FFP, median 8.5 [IQR 5-
11.5]; PLT, median 1 [IQR 1-2]) and historical cohort 2 (RBCs,
median 8 [IQR 6-12]; FFP, median 6 [IQR 4-10]; PLT, median
0 [IQR 0-1]; Table 4). Obstetric and medical interventions
performed in the study cohort were able to stop bleeding in the
majority of patients. Administration of FXIII concentrate or of
a third dose of rFVIIa had never been necessary (Table 2).
Of particular note, the amount of blood products transfused
after the administration of fibrinogen and/or rFVIIa was not
different between the 3 groups. For instance, looking only at
the patients who received rFVIIa, the amount of blood products
transfused after rFVIIa was similar in the 3 cohorts (Table 4).
The introduction of this standardized management protocol
reduced the need of blood products in patients with sPPH. The
size effects calculated between the 3 cohorts range from
medium to large (Table 5).
Of all 74 patients, only 1 (1.4%) in the historical cohort 2
experienced a clinically manifest pulmonary embolism diag-
nosed on day 10 after delivery. Interestingly, this patient had
neither received tranexamic acid nor fibrinogen and rFVIIa;
however, she had undergone emergency hysterectomy. There
were no maternal deaths.
Discussion
Postpartum hemorrhage remains one of the most unpredictable
emergencies in obstetrics. During sPPH, blood loss may
Table 4. Units of Allogeneic Blood Products Transfused Before Application of Hemostatic Drugs (Fibrinogen and/or rFVIIa if Necessary), After
rFVIIa Exposure and Bleeding Duration Before rFVIIa in the 3 Periods.a
Transfused Allogeneic Blood Products
Before Hemostatic Drugs (Fibrinogen and/or rFVIIa) Historical Cohort 1
n ¼ 20
Historical Cohort 2
n ¼ 27
Study Cohort
n ¼ 27
P Value
RBCs, median (IQR) 9 (6.5-15) 8 (6-12) 4 (3-7) .002
FFP, median (IQR) 8.5 (5-11.5) 6 (4-10) 4 (2-6) .002
PLT, median (IQR) 1 (1-2) 0 (0-1) 0 (0-1) .010
After rFVIIa Historical Cohort 1
n ¼ 20
Historical Cohort 2
n ¼ 15
Study Cohort
n ¼ 14
P Value
RBCs, median (IQR) 1 (0-2.75) 4 (2-8) 2 (0-5.25) .071
FFP, median (IQR) 0.5 (0-2) 2 (0-4) 1 (0-4) .482
PLT, median (IQR) 0 (0-1) 0 (0-1) 0 (0-1) .698
Bleeding duration before rFVIIa (minutes), median (IQR) n ¼ 20
328 (151-640)
n ¼ 15
190 (150-240)
n ¼ 14
135 (108-173) .021
Abbreviations: FFP, fresh frozen plasma; PLT, platelet concentrates; RBC, red blood cell concentrates; rFVIIa, recombinant activated factor VII.
aResults expressed as medians and interquartile ranges (IQRs).
Table 3. Estimated Blood Loss and Fluid Replacement in the 3 Periods (Results Expressed as Medians and Interquartile Ranges, IQR).
Historical Cohort 1
n ¼ 20
Historical Cohort 2
n ¼ 27
Study Cohort
n ¼ 27 P Value
Estimated blood loss (mL), median (IQR) 4500 (3000-5500) 6000 (3000-6500) 3000 (2000-4000) .004
Normal saline–glucose (mL), median (IQR) 0 (0-900) 500 (400-1000) 500 (0-500) .072
Ringer’s solution (mL), median (IQR) 1800 (1000-3000) 2000 (1200-3000) 2000 (1000-3000) .558
Colloids (mL), median (IQR) 1850 (1000-2375) 1500 (1000-2000) 1000 (500-1500) <.001
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become uncontrollable and life-threatening. A gold standard
therapy is not well established, and it is suggested to implement
a local protocol to avoid time loss and management errors. To
evaluate a standardized management protocol at our institution,
we compared patients with sPPH to 2 different cohorts treated
before adoption of this strategy. After implementation of the
standardized protocol providing early and sequential interven-
tions, we noted a reduction in the bleeding duration and sever-
ity, in the total amount of transfused labile blood products and,
most importantly, in the EPH rate. This standardized manage-
ment protocol enabling early recognition of PPH, rapid and
coordinated response with predefined therapeutic procedures
improved globally the approach to the severe bleeding and
finally the clinical course. Although our study shows that this
protocol was associated with a reduction in the need of blood
components in our cohort, we were not able to define the role of
a single step and of each individual hemostatic agent. It is
important to note that the protocol incorporates several proce-
dures to maternity care and it is not simply a massive transfu-
sion protocol. Slightly more patients in the study cohort were
subjected to pelvic vessel ligation or embolization as compared
to patients in the 2 historical cohorts (P ¼ .092). Thus we
cannot exclude a benefit of these interventional measures for
the better outcome of our study cohort. The clinical benefit may
be related to the standardized procedures and the sum of the
individual therapeutic measures during the study period.
Obstetric and hemostatic interventions combining limitation
of hydroxyethyl starch, immediate administration of tranexa-
mic acid, early labile blood products with a 1:1 ratio of RBCs to
FFP, and—if necessary—early administration of low-dose
fibrinogen reduced or stopped the bleeding in about 50% of
patients (n ¼ 13, Table 2). It is important to note that the
protocol of the study cohort differs from current international
guidelines regarding several points: First, the volume replace-
ment with colloids was limited to a maximum of 20 mL/kg
body weight. Second, all patients received promptly tranexa-
mic acid. Furthermore, the “emergency package” contained
rFVIIa at a dose of 60 mg/kg body weight ready to be adminis-
tered after 2 g of fibrinogen concentrate, 4 units of RBCs, 4
units of FFP, and 1 PLT concentrate, if blood loss persisted.
The early administration of products, particularly of rFVIIa,
diverges from current guidelines that suggest that rFVIIa can
be considered for ongoing PPH unresponsive to standard ther-
apy8 or can be considered as the second-line hemostatic ther-
apy.22 We believe that an early and adequate intervention to
limit the blood loss may reduce the progression to uncontrol-
lable bleeding. In patients necessitating rFVIIa (n ¼ 14, Table
2), the bleeding duration before rFVIIa was shorter compared
to historical cohorts 1 and 2 (Table 4). In future studies, we
suggest to consider the time point for rFVIIa administration
which represents another important difference between this
protocol and international guidelines advocating the use of
rFVIIa for ongoing PPH8 or as a last resort after conventional
therapies fail.33 In this study, we can observe that administra-
tion of rFVIIa after a long-lasting and massive blood loss, as a
last resort to prevent hysterectomy (as performed in the histor-
ical cohort 1) and particularly its liberal use in the absence of
any guideline (as in the historical cohort 2), was less effica-
cious. Of particular note, the smaller amount of blood products
transfused in the study cohort (Table 2) was due to less blood
products transfused before—and not after—additional hemo-
static intervention (Table 4). Therefore, we speculate that the
timing of the therapeutic intervention is relevant for reducing
the bleeding severity and controlling coagulopathy. It seems
that an aggressive management at the initial stage of bleeding
would limit the coagulopathy and the progression to life-
threatening hemorrhage.
Of note, no patients with preexisting bleeding disorders
were present in our cohort. We believe that low-dose rFVIIa
should not yet be discarded as an early measure in therapeutic
algorithms for patients with PPH and should not be restricted to
specific hematological indications.27 Our approach in the study
cohort—offering a standardized management protocol for
obstetrician, anesthesiologist, and the other treating staff with
defined procedures and immediate application of tranexamic
acid, RBCs, FFP, PLT, and low-dose fibrinogen—reduced the
use of rFVIIa significantly to about 50% and improved out-
come. Prospective clinical trials with defined PPH resuscitation
Table 5. Allogeneic Transfusiona,b
Study Cohort
n ¼ 27
Historical Cohort 1
n ¼ 20
Effect Size
Hedges’ g
Historical Cohort 2
n ¼ 27
Effect Size
Cohen d
Total
RBCs, mean (SD) 7.6 (7.4) 13.2 (7.6) 0.75 11.1 (6.7) 0.50
FFP, mean (SD) 5.7 (5.4) 11.1 (7.7) 0.83 8.7 (5.6) 0.55
PLT, mean (SD) 0.96 (1.29) 2.05 (2.14) 0.64 0.93 (1.00) 0.03
Before hemostatic drugs (fibrinogen and/or rFVIIa)
RBCs, mean (SD) 5.7 (3.6) 10.7 (5.6) 1.09 8.6 (4.8) 0.68
FFP, mean (SD) 4.4 (3.2) 8.2 (3.6) 1.12 7.2 (4.7) 0.70
PLT, mean (SD) 0.55 (0.75) 1.6 (1.93) 0.77 0.70 (0.95) 0.17
Abbreviations: FFP, fresh frozen plasma; PLT, platelet concentrates; RBC, red blood cell concentrates; rFVIIa, recombinant activated factor VII; sPPH, severe
postpartum hemorrhage.
aResults expressed as means and standard deviation (SD).
bSize effect between groups calculated for all transfused allogeneic products (A) and for these transfused before hemostatic drugs (B).
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protocols are needed to confirm the beneficial effects observed
in our cohort.
While this study reporting everyday clinical practice at our
institution documents an improvement across 3 consecutive
periods with evolving PPH management strategy, it has limita-
tions and weaknesses as well. Its observational character, the
lack of blinding and randomization, and the small sample size
render our findings only hypothesis generating. A prospective
randomized controlled trial will be needed to ultimately vali-
date the usefulness of such a standardized protocol. Moreover,
as mentioned above, we cannot distinguish the effect of a single
hemostatic agent or specific measure of our protocol. Never-
theless, the sum of all elements of the algorithm is effective and
our results are in-line with recent studies that describe reduced
use of blood products and improved patient safety following
comprehensive maternal hemorrhage protocols.34,35 The bene-
ficial effects of this standard protocol are indicated not only by
the diminution of the estimated blood loss but also by the lower
number of EPH.
In conclusion, the implementation of a standardized inter-
disciplinary approach to the management of sPPH is beneficial
and therefore recommended. This study suggests that the pro-
tocol should consider in addition to uterotonic drugs immediate
administration of tranexamic acid, transfusion of RBC concen-
trates, FFP, PLT concentrates, and sequential administration of
low-dose fibrinogen concentrate and rFVIIa. Timely applica-
tion of these measures appears to reduce blood product
administration and EPH rates.
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